Literature DB >> 7647282

Fibrosing cholestatic hepatitis and HBV after bone marrow transplantation.

W G Cooksley1, C A McIvor.   

Abstract

Liver failure caused by reactivation of hepatitis B virus (HBV) is an uncommon complication of bone marrow transplantation. Fibrosing cholestatic hepatitis is a recently described liver lesion that develops in some patients undergoing liver transplantation for chronic HBV infection. The lesion is characterised by peri portal fibrosis, ballooning degeneration of hepatocytes, prominent cholestasis and paucity of inflammation. Recent data suggests it is a cytopathic effect of the pre-core mutant form of HBV with over-expression of viral antigens. Although only one case has so far been described associated with bone marrow transplantation (BMT) it is likely that increasing use of BMT in people with chronic HBV infection will lead to further patients being recognised.

Entities:  

Mesh:

Year:  1995        PMID: 7647282     DOI: 10.1016/0753-3322(96)82604-7

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  6 in total

1.  NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report.

Authors:  Howard M Shulman; Diana M Cardona; Joel K Greenson; Sangeeta Hingorani; Thomas Horn; Elisabeth Huber; Andreas Kreft; Thomas Longerich; Thomas Morton; David Myerson; Victor G Prieto; Avi Rosenberg; Nathaniel Treister; Kay Washington; Mirjana Ziemer; Steven Z Pavletic; Stephanie J Lee; Mary E D Flowers; Kirk R Schultz; Madan Jagasia; Paul J Martin; Georgia B Vogelsang; David E Kleiner
Journal:  Biol Blood Marrow Transplant       Date:  2015-01-29       Impact factor: 5.742

Review 2.  Review.

Authors:  Lawrence U Liu; Thomas D Schiano
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-03

3.  A prophylactic approach for bone marrow transplantation from a hepatitis B surface antigen-positive donor.

Authors:  Abhasnee Sobhonslidsuk; Artit Ungkanont
Journal:  World J Gastroenterol       Date:  2007-02-21       Impact factor: 5.742

4.  How I treat hepatitis C virus infection in patients with hematologic malignancies.

Authors:  Harrys A Torres; George B McDonald
Journal:  Blood       Date:  2016-07-21       Impact factor: 22.113

5.  Fibrosing cholestatic hepatitis following cytotoxic chemotherapy for small-cell lung cancer.

Authors:  Jaime Ceballos-Viro; José-M López-Picazo; José-L Pérez-Gracia; Jesús-J Sola; Gregorio Aisa; Ignacio Gil-Bazo
Journal:  World J Gastroenterol       Date:  2009-05-14       Impact factor: 5.742

6.  A woman with recent jaundice and pruritus.

Authors:  Bita Behnava; Seyed Moayed Alavian
Journal:  Hepat Mon       Date:  2010-03-01       Impact factor: 0.660

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.